Memorial Sloan Kettering Westchester

West Harrison, NY

Sorting 9 by

Accepting patients

Stopping Maintenance Therapy

Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission
Learn more
  • Maintenance

Accepting patients

NUTRIVENTION-4

A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide
Learn more
  • Monoclonal Antibody
  • CD38
  • Maintenance
  • Phase 2
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trials

Accepting patients

Melphalan With or Without Siltuximab

Phase II Randomized Trial of Population PK Dosed Melphalan With Interleukin-6 Blockade With Siltuximab Vesrus BSA Based Melphalan in Patients With Multiple Myeloma Over Age 60 Undergoing Autologous Stem Cell Transplantation
Learn more
  • Monoclonal Antibody
  • Interleukin 6 (IL-6)
  • Post-Autologous Stem Cell Transplant
  • Pre-Autologous Stem Cell Transplant
  • Phase 2

Accepting patients

Talquetamab Consolidation After BCMA CAR-T

Talquetamab Consolidation After BCMA CART Cell Therapy for Relapsed or Refractory Multiple Myeloma
Learn more
  • Bispecific Antibody
  • GPRC5D
  • Post-CAR T
  • Phase 2

Accepting patients

MagnetisMM-30

A Phase 1B, Open-Label Study of Elranatamab in Combination with Iberdomide in Participants with Relapsed Refractory Multiple Myeloma
Learn more
  • Bispecific Antibody
  • BCMA
  • CD3
  • Phase 1

Accepting patients

Isatuximab After Allogeneic Stem Cell Transplant

Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation
Learn more
  • Monoclonal Antibody
  • CD38
  • Phase 2

Accepting patients

CyBorD Plus Daratumumab

A Phase II Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab for Patients With Monoclonal Gammopathy of Renal Significance (MGRS)
Learn more
  • Monoclonal Antibody
  • CD38
  • Quadruplet Therapy
  • Phase 2

Accepting patients

Identifying Barriers to Cellular Therapy

Prospective Multi-Center Study to Identify Barriers to Cellular Therapies in Patients With Plasma Cell Disorders PROACT PCD
Learn more
  • Observational Trial

Accepting patients

Genetic Studies

Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
Learn more